MAPT and Alzheimer disease: TFEB has also been validated as an emerging therapeutic target to enhance lysosomal biogenesis and autophagy in different disorders — such as Alzheimer’s disease, in which its astrocytic expression decreases misfolded Tau spreading (52) — but also for lysosomal storage disorders, such as Pompe Disease (53), as well as for ischemic injury (54), alcoholic liver disease (55, 56), and osteoarthritis (57).